$32.31
1.58% yesterday
Nasdaq, May 22, 10:16 pm CET
ISIN
GB00BMVP7Y09
Symbol
RPRX
Sector
Industry

Royalty Pharma plc - Ordinary Shares - Class A Stock price

$32.31
+0.12 0.37% 1M
+5.88 22.25% 6M
+6.80 26.66% YTD
+4.98 18.22% 1Y
-7.74 19.33% 3Y
-12.19 27.39% 5Y
-12.19 27.39% 10Y
Nasdaq, Closing price Thu, May 22 2025
-0.52 1.58%
ISIN
GB00BMVP7Y09
Symbol
RPRX
Sector
Industry

Key metrics

Market capitalization $18.17b
Enterprise Value $23.97b
P/E (TTM) P/E ratio 17.19
EV/FCF (TTM) EV/FCF 85.68
EV/Sales (TTM) EV/Sales 10.59
P/S ratio (TTM) P/S ratio 8.03
P/B ratio (TTM) P/B ratio 2.74
Dividend yield 2.60%
Last dividend (FY24) $0.84
Revenue growth (TTM) Revenue growth 1.13%
Revenue (TTM) Revenue $2.26b
EBIT (operating result TTM) EBIT $1.90b
Free Cash Flow (TTM) Free Cash Flow $279.75m
Cash position $1.82b
EPS (TTM) EPS $1.88
P/E forward 26.93
P/S forward 6.09
EV/Sales forward 8.04
Short interest 4.36%
Show more

Is Royalty Pharma plc - Ordinary Shares - Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Royalty Pharma plc - Ordinary Shares - Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Royalty Pharma plc - Ordinary Shares - Class A forecast:

Buy
78%
Hold
22%

Financial data from Royalty Pharma plc - Ordinary Shares - Class A

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
2,264 2,264
1% 1%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 290 290
31% 31%
13%
- Research and Development Expense 52 52
0% 0%
2%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT 1,900 1,900
102% 102%
84%
Net Profit 1,093 1,093
37% 37%
48%

In millions USD.

Don't miss a Thing! We will send you all news about Royalty Pharma plc - Ordinary Shares - Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Royalty Pharma plc - Ordinary Shares - Class A Stock News

Neutral
GlobeNewsWire
7 days ago
NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction.
Neutral
GlobeNewsWire
10 days ago
NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
Neutral
GlobeNewsWire
11 days ago
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company.
More Royalty Pharma plc - Ordinary Shares - Class A News

Company Profile

Royalty Pharma Plc provides drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The firm's portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Symdeko and Trikafta, and four development-stage product candidates. It focuses on acquiring royalty-generating products segment. The firm invests in biopharmaceutical products. The company was founded by Pablo Gerardo Legorreta in 1996 and is headquartered in New York, NY.

Head office United Kingdom
CEO Pablo Legorreta
Founded 1996
Website www.royaltypharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today